Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Gene Therapies
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(109)
•••
Comment by prophetoffactzon Sep 03, 2022 11:37am
124 Views
Post# 34940025

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Gene Therapies

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Gene Therapies

"Yo, MT, I wrote 6 and 8 years ago that the value of LSDs was declining and that if Bioasis didn't get going they'd lose that commercial opportunity...There is some money to made in LSDs, but the drugs are so expensive that it is one area where gene therapies could be a hands-down winner."

Eight years ago you were touting gene therapy and there still is no LSD gene therapy on or near to market? Your track record predicting gene therapy is as bad as your predicitons about BTI. How much did analysts attribute to the value of Denali's LSD programs at Denali's stock price high and currently? Where did all the gene therapies for LSDs go that you are so spooked about 8 years ago? Why did they fail? Who has the lead gene therapy now for LSDs?

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities